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Abstract Background and objective: Glioblastoma (GBM) is one of the 
malignant tumors causing death worldwide. Most patients were found in the 
middle and late stages and had poor prognosis. The purpose of this study was to 
investigate the expression and significance of CTSC in GBM. Methods: The 
information about CTSC in Oncomine database was collected and analyzed 
twice. The role of CTSC in GBM was meta-analyzed. The expression of CTSC 
in glioma cell lines was retrieved by CCLE database, and the survival of patients 
was analyzed by TCGA database. Results: A total of 1,459 different types of 
CTSC were collected in Oncomine database, 134 of which had statistical 
differences in CTSC expression, 89 of which had increased CTSC expression 
and 45 of which had decreased CTSC expression. A total of 50 studies involving 
the expression of CTSC in GBM cancer and normal tissues included 1,189 
samples. Compared with the control group, CTSC was highly expressed in GBM 
(P < 0.05). Moreover, CTSC was highly expressed in glioma cell lines. There 
was a correlation between the expression of CTSC and the overall survival rate 
of GBM. The overall survival rate of patients with high expression of CTSC was 
worse, while the prognosis of patients with low expression of CTSC was better 
(P < 0.05). Conclusion: Through the in-depth mining of oncomine gene chip 
database, we propose that CTSC is highly expressed in GBM tissues and is 
related to the prognosis of GBM, which may provide an important theoretical 
basis for the treatment of glioma.. 
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1. Introduction 
Glioblastoma (GBM) is a serious threat to human health and one of the most lethal malignant tumors, which has caused 
tremendous economic burden to society[1]. Although many new therapies have been found in recent years, most of them are 
in the middle and late stages, and the prognosis has not been significantly improved. Studying the mechanism of the 
occurrence and development of CTSC at the molecular level is conducive to discovering new molecular targets and 
developing new therapeutic methods. It is very important to reduce patients' pain and prolong patients' survival time. 
Oncomine database is the largest oncogene chip database and integrated data mining platform in the world, aiming at mining 
cancer gene information[2]. So far, 715 gene expression datasets and 86,733 samples of cancer and normal tissues have been 
collected in this database. Using Oncomine database, we can compare common cancer types and their normal tissues for 
differentially expressed sorting. We can also explore various cancer subtypes and analyze them based on clinical and 
pathological data. We can do differentially expressed sorting and co-expression analysis, find differentially expressed genes 
in a certain cancer, determine the target genes, and then determine the research direction. It can not only save the cost of 
scientific research, but also save the cost of scientific research. And its information is more comprehensive. 
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Cathepsin is a kind of proteolytic enzyme widely existing in many kinds of tissue and cell lysozymes, which plays an 
important role in various physiological activities of the body[3]. There are many kinds of cathepsin with tissue specificity. 
Different cells, even the same cell, express different proteases in different physiological environments. Cathepsin can be 
divided into three categories according to the different catalytic centers: serine cathepsin (cathepsin A and G), cysteine 
cathepsin (cathepsin B, C, L, H, S), and aspartate cathepsin (cathepsin D and E). So far, more than 10 kinds of cathepsin have 
been found, but the understanding of their physiological functions is far from enough. Cathepsin C, also known as dipeptidyl 
peptidase I (DPPI), was discovered in the 1940s and is a lysosomal cysteine protease[4]. Previous studies have shown that it 
is highly expressed in inflammatory cells and may be related to the activation of granulase. In addition, although the enzyme 
was widely expressed in many tissues, its expression and function were not clear, and there was little systematic study in 
glioblastoma tissue. 
In this study, Oncomine database and TCGA database were used to analyze the expression and prognosis of CTSC in GBM, 
and the possible relationship between CTSC and GBM was meta-analyzed by secondary analysis, which provided clues and 
basis for further study of the mechanism of CTSC in the occurrence and development of GBM. 
2. Material and Methods 
2.1. Plant Material and Experimental Design 
Oncomine database extracts data Oncomine database is a gene chip-based database and integrated data mining platform, in 
which data can be screened and mined according to their own needs. In this study, we set the screening conditions as 
follows: (1) Cancer Type: Brain and CNS Cancer; (2) Gene: CTSC; (3) Data Type: RNA and DNA copy number; (4) 
Analysis Type: Cancer vs Normal Analysis; (5) Critical value setting conditions (P < 1E-4, fold change > 2, gene rank = 
top 10%). Select the bar chart to show the results. 
The expression of CTSC in glioma cell lines was retrieved from CCLE database and analyzed by CCLE website 
(https://portals.broadinstitute.org/ccle) [5]. 
TCGA database was used for patient survival analysis. The GBM dataset of TCGA database was analyzed online by 
proggene V2 website (http://watson.compbio.iupui.edu/chirayu/proggene/database/?Url=proggene)[6]. The screening 
conditions are as follows: (1) Cancer: Brain Cancer; (2) Gene: CTSC; (3) Survival: OS. 
Statistical methods :The difference of CTSC expression between normal tissues and GBM patients was analyzed by t-test. 
The relationship between CTSC expression and GBM prognosis was analyzed by Kaplan-Meier model. All the data were 
analyzed by SPSS 20.0, and the difference was statistically significant with bilateral P < 0.05. 
3. Results 
The results of CTSC expression in common tumors Oncomine database collected 1459 different types of research results 
(Figure 1). 134 of them showed significant difference in CTSC expression, and CTSC expression was detected in Oncomine 
database.There were 89 increased studies and 45 decreased expression studies. 
The results of CTSC expression in GBM were found in Oncomine database. Since 2003, there have been seven studies 
involving the expression of CTSC in GBM and normal tissues (Figure 2), with a total of 1,795 samples. The articles were 
published in Cancer Cell, 2006, J Clin Oncol, 2008, TCGA Brain 2, No Associated Paper, 2013, etc. A meta-analysis of 7 
studies in Oncomine database showed that the median value of CTSC gene ranked 611, P=5.03E-5 among all differentially 
expressed genes, suggesting that CTSC was highly expressed in GBM. 
The expression of CTSC in different cancer cell lines is shown in Figure 3. The expression of CTSC in different cancer cell 
lines is shown in CCLE database. CTSC is highly expressed in GBM cell lines. 
The relationship between CTSC and prognosis of GBM patients  Kaplan-Meier Plotter data showed that CTSC expression 
level had a significant impact on the overall survival time of GBM patients. Compared with the low expression group, the 
total survival time of GBM patients in CTSC high expression group was significantly reduced. (Figure 4). 
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Figure 1. Expression data for CTSC in a variey of normal and cancerous human tissues in database Oncomine 
 
Figure 2. Expression of CTSC in GBM in the studies identified in the Oncomine database. 1-7 represent the 7 studies on the expressions of CTSC 
in GBM. Darker red indicates higher GBM expression in the chips 
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Figure 3. The expression of CTSC in multiple cancer cell lines 
 
Figure 4. Relationship between the expression of CTSC and the prognosis of GBM 
4. Discussion 
Glioblastoma is one of the most lethal malignant tumors in the world. Epidemiological statistics show that the incidence of 
glioblastoma in gliomas is increasing. For a long time, the prognosis of GBM has been poor. With the development of 
molecular biology technology, a number of glioma-related genes such as PTEN, PDCD4, TP53 have been found one after 
another, and some targeted therapeutic drugs have been developed, which greatly improve the prognosis of glioma 
patients[7]. However, mutations of these genes only exist in some glioma patients. Therefore, searching for key molecules 
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or targets for the occurrence and development of glioblastoma has important theoretical and clinical significance for the 
development of new targeted drugs for the treatment of GBM, and has always been a research hotspot at home and abroad. 
Cathepsin C is an important member of the cysteine protease family. The mature human cathepsin C gene (CTSC) has a 
molecular weight of 200 kDa, and each molecule consists of 206 amino acid residues; four tetramers consisting of four 
identical subunits, each consisting of three different peptide chains: a light chain, a heavy chain and an exclusion domain; 
four catalytic active sites grooves on the protein surface block the extension of the groove. The endonuclease activity was 
removed by stretching. The expression of cathepsin is tissue-specific. Cathepsin is expressed differently in different 
physiological environments in different cells and even in the same cell. The expression of cathepsin is closely regulated by 
cells in order to cope with the changes of different physiological environments. Cathepsin C mediates target cell death by 
treating granulase A and B[8]. Cell death is an important process for the survival of multicellular organisms, in which the 
lysis of killer cells to target cells is an important way of cell death, such as cytotoxic T lymphocytes (CTLs) and natural 
killer cells (NK), which are also part of the cellular immune barrier to viruses and cancer cells. 
Natural Killer cells lyse cells in two ways: through FAS ligands and receptors, and through membrane penetrating proteins 
and granzymes[9]. The latter can only be accomplished with the help of cathepsin C. CTLs first form synapses with target 
cells. Cathepsin C, granzyme A and B, and transmembrane proteins are all encapsulated in synapses. Cathepsin C 
hydrolyzes the dipeptides at the N-terminal of granzyme and makes it in a fully functional activation state. Then, the 
transmembrane proteins form a maximum 16-nm transmembrane channel through the calcium ion binding to the 
phospholipid head of the cell membrane. By endocytosis, the membrane cleft was repaired, and the activated granzymes A 
and B successfully entered the target cells. These activated granzymes which reached the cytoplasm of the target cells 
activated downstream apoptotic pathways and eventually led to the death of the target cells. 
Pham observed cathepsin C gene knockout (CTSC-/-) mice and wild type mice. It was found that there was no difference 
in the number of granulase A and B in CTLs cells between the two mice[10]. However, granulase in CTSC-/-mice CTLs 
cells had no function and could not cause cell death after entering the target cells. It was speculated that cathepsin C could 
be involved in CTLs-mediated cell death through granulase. Important role. In 1986 and 1987, Doughty MJ and others 
found that cathepsin C had some relationship with cell growth[11]. They cultured fibroblasts from adult male patients with 
Duchenne muscular dystrophy and normal males, and measured the activity of cathepsin C in both cells at week 10. It was 
found that the activity of cathepsin C in skin fibroblasts derived from pseudohypertrophic muscular dystrophy was 
significantly lower than that in normal skin fibroblasts[12]. This study confirmed that Duchenne-derived cells contained 
low levels of enzyme activity, which was not due to the redistribution of enzyme in cells. Glycine-phenylalanine had a 
lower activity in Duchenne-derived cells. After measuring the activity of cathepsin C at different time points and evaluating 
the growth time and state of corresponding cells, it was found that the activity level of cathepsin C could reflect the growth 
state of cells. It has also been reported that the activity of cathepsin C changes with the aging of culture medium in vitro, 
and in tissue, the activity of cathepsin C changes with the growth of cells. 
Although most studies have found that CTSC is highly expressed in many tumors[13], including GBM, there is a lack of 
high reliability due to the small sample size in independent studies, which easily leads to sampling errors. Oncomine 
database is the largest gene chip database and integrated data mining platform in the world. First, we used Oncomine 
database to mine GBM gene expression information in colorectal cancer, breast cancer, gastric cancer and other common 
tumors. The results showed that 89 of 134 studies with statistical differences showed that CTSC was highly expressed in 
common tumors. The results of GBM chip detection were analyzed by Oncomine database. It was also proved that CTSC 
was highly expressed in GBM tissues in more than 1,000 samples. At the same time, we used CCLE cell database to confirm 
the high expression of CTSC in glioma cell lines. The PROGgene database (http://www.compbio.iupui.edu/proggene) is a 
web application that can be used for studying prognostic implications of mRNA biomarkers in a variety of cancers. We 
have compiled data from public repositories such as GEO, EBI Array Express and The Cancer Genome Atlas for creating 
this tool. With 64 patient series from 18 Canc Genome Atlas In our database, this tool provides the most comprehensive 
resources available for survival analysis to date. In this paper, the prognostic value of CTSC in GBM is first found through 
PROGgene database. The results showed that the expression of CTSC was clearly correlated with the overall survival rate 
of GBM, and the overall survival time of patients with high expression of CTSC was significantly reduced. The high 
expression of CTSC may affect the occurrence of tumors. Perhaps the abnormal expression of CTSC gene will directly 
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affect the process of cell death and eventually cause tumorigenesis. All our data are from gene chips, and the research 
methods are consistent, and include the largest sample size so far, eliminating errors caused by sample size problems, and 
increasing the credibility of the conclusions. 
5. Conclusion 
We propose that CTSC is highly expressed in GBM tissues and is related to the prognosis of GBM through in-depth mining 
of CTSC-related information in GBM tissues. Using the database for large sample analysis can avoid the error caused by 
the small sample size of a single study and provide an important theoretical basis for clinical treatment. The specific 
mechanism of CTSC in the development of GBM disease needs further experiments to prove in the future. 
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